VERAXA Biotech (NASDAQ: VRXA) announced today that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone under its collaboration with OmniAb. OmniAb has successfully completed its discovery work, allowing the program to advance into its next phase, the company said. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach, which is intended to improve precision in treating solid tumors.
The collaboration, launched in May 2025, leverages OmniAb’s antibody discovery technologies, including its OmniClic platform, while VERAXA applies its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. Under the agreement, VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue from resulting products. For more details, the full press release is available at https://ibn.fm/qMRuJ.
The advancement of VXA-222 is significant because bispecific ADCs represent a promising next-generation approach in oncology. By targeting two distinct tumor antigens simultaneously, the molecule can potentially increase specificity for cancer cells while reducing off-target effects on healthy tissue. The “AND-gate” mechanism requires both antigens to be present for activation, which may further enhance selectivity. This could address a major challenge in solid tumor treatment: the difficulty of targeting malignant cells without harming normal cells.
For the biopharmaceutical industry, this milestone highlights the growing trend of collaborations leveraging specialized platforms. OmniAb’s discovery technologies combined with VERAXA’s conjugation expertise illustrate how partnerships can accelerate development of complex biologics. VERAXA’s pipeline includes bispecific T cell engagers and other innovative formats, and the company is rapidly advancing its ADCs and proprietary BiTAC formats into clinical development. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For investors, the news provides a positive signal of progress in VERAXA’s pipeline. However, as with all early-stage biotech programs, risks remain. The company’s forward-looking statements caution that actual results may differ materially from expectations due to various factors, including those detailed in its SEC filings. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
The broader impact of this advancement could be substantial if VXA-222 demonstrates clinical success. Precision-targeted therapies like VXA-222 have the potential to improve outcomes for patients with solid tumors, which account for the majority of cancer diagnoses. By reducing side effects and increasing efficacy, such therapies could become a cornerstone of future oncology treatment regimens. As VERAXA moves VXA-222 into its next phase, the industry will be watching closely for preclinical and clinical data that could validate the “AND-gate” approach and open new avenues for bispecific ADCs.
